Clinical trials: Platinum-Sensitive Primary Peritoneal Carcinoma
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent…
- Trial name
- NCT00006812
- Testing
- capecitabine
- Where
- 31 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Cancer
Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer
The purpose of this study is to determine if the combination of Abraxane and Carboplatin together will improve the chances of controlling recurrent ovarian/fallopian tube/peritoneal cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00466986
- Testing
- Abraxane
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Southeastern Gynecologic Oncology
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase II trial to study the effectiveness of bortezomib in treating patients who have persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer.
- Trial name
- NCT00023712
- Testing
- bortezomib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients who have recurrent…
- Trial name
- NCT00005029
- Testing
- topotecan hydrochloride
- Where
- 74 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00020696
- Testing
- cisplatin, tirapazamine
- Where
- 54 sites in United States, Australia and 2 more
- Sponsor
- Gynecologic Oncology Group